current site language is FDA-compliant
United States Legal Status and Compounded Peptide Considerations FDAs May 2026 bulk-substance document lists GHK-Cu except for injectable routes of administration as a 503A category 1 substance under evaluation and says FDA intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027 about potential inclusion on the 503A bulks list [19]
[DOI] [PubMed] [Google Scholar] 131.Ghosh M, Niyogi S, Bhattacharyya M, Adak M, Nayak DK, Chakrabarti S, et al
In peptide therapy, compounding allows pharmacies to create peptide formulations that are: More affordable than brand-name versions Customized to specific dosing needs Available when brand shortages occur Combined with other compounds for enhanced effect The Legal Framework: 503A vs
It focuses on the limitations of current obesity drugs like semaglutide and tirzepatide, and the Join the conversation